Roche acquires Inflazome to gain control over inflammatory treatments

By Nikita Chaurasia  Date: 2020-09-22

Roche acquires Inflazome to gain control over inflammatory treatments

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million).

As per the agreement, Roche will acquire complete rights to Inflazome’s portfolio of oral NLRP3 inflammasome inhibitors, which are currently being developed for treating conditions such as Parkinson’s and other diseases, sources claimed.

Since its inception in 2016, Inflazome has been gaining worldwide recognition owing to its expertise in inflammasome inhibitors.  The firm is currently developing an oral NLRP3 inflammasome inhibitor in order to meet the unmet demands for various inflammatory diseases. In fact, the company claims the inhibitor has already completed Phase 1 human trails as well as various early-stage programmes.

Inflazome is also developing drugs which targets inflammasomes associated with arthritis, asthma, Alzheimer’s, Parkinson’s, and bowel disease as well as other chronic inflammatory conditions, cited sources with relevant information.

Matt Cooper, CEO at Inflazome was reported saying that the company is thrilled to enter a joint venture agreement with one of the prominent pharmaceutical giant Roche. He added that the acquisition will allow Inflazome to quickly and effectively develop its products in order to aid patients with debilitating diseases.

It is to be noted that earlier in July, Roche and its subsidiary Genentech Inc. entered a joint venture agreement with UCB, a Belgian company to produce and commercialize an antibody drug UCB0107 for treating Alzheimer’s disease

Several other pharmaceutical companies are also working on similar drug developments. In fact, IFM Therapeutics sold its subsidiaries with NLRP3 assets to Novartis International AG and Bristol Myers Squibb (BMS).

Source credits –

https://www.fiercebiotech.com/biotech/roche-pays-eu380m-for-nlrp3-biotech-inflazome-claiming-a-leading-position-hot-field

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...